Quantinuum (QNT) CSO adds 126,460-share stake via grant and open-market buy
Rhea-AI Filing Summary
Quantinuum Inc. Chief Strategy Officer Kevin Scott Dehoff increased his direct stake in Class A Common Stock through both a grant and a market purchase. On June 3, 2026, he acquired 111,460 restricted shares in connection with a recapitalization transaction at a stated price of $0.00 per share. On June 5, 2026, he made an open-market purchase of an additional 15,000 shares at $60.00 per share. Following these transactions, Dehoff directly owns 126,460 Class A shares, aligning his interests more closely with shareholders ahead of the company’s initial public offering.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Class A Common Stock | 15,000 | $60.00 | $900K |
| Grant/Award | Class A Common Stock | 111,460 | $0.00 | -- |
Footnotes (1)
- This transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended, in connection with the Issuer's initial public offering, and is reported herein pursuant to Rule 16a-2(a). Represents an acquisition of restricted shares of Class A Common Stock pursuant to a recapitalization transaction.
Key Figures
Key Terms
open-market purchase financial
recapitalization transaction financial
initial public offering financial
Rule 16a-2(a) regulatory
Section 12 of the Securities Exchange Act of 1934 regulatory
FAQ
What insider transactions did Quantinuum (QNT) Chief Strategy Officer Kevin Dehoff report?
Kevin Dehoff reported two transactions involving Quantinuum Class A Common Stock. He received 111,460 restricted shares in a recapitalization transaction and separately bought 15,000 shares in the open market at $60.00 per share, increasing his direct ownership to 126,460 shares.
What was the size of Kevin Dehoff’s equity grant in Quantinuum (QNT)?
Kevin Dehoff was granted 111,460 restricted shares of Quantinuum Class A Common Stock. The grant occurred in connection with a recapitalization transaction and was reported at a stated price of $0.00 per share, reflecting a non-cash equity award to the executive.